← Back to Clinical Trials
Recruiting NCT04701684

NCT04701684 WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04701684
Status Recruiting
Phase
Sponsor Philips Clinical & Medical Affairs Global
Condition Stroke, Acute
Study Type INTERVENTIONAL
Enrollment 594 participants
Start Date 2021-06-23
Primary Completion 2027-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Direct to Angio Suite (DTAS) Philips' CBCT triageConventional CT/MR triage

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 594 participants in total. It began in 2021-06-23 with a primary completion date of 2027-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.

Eligibility Criteria

Inclusion Criteria: * Subject is 18 years of age or older, or of legal age to give informed consent per state or national law. * Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points. * Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2). * Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) \< 6 hours from symptom onset OR wake-up stroke with time last known well of \< 12 hours and symptoms discovered within 6 hours from arrival time at a stroke center. Symptom onset is defined as point in time the patient was last known well (at baseline). * Informed consent obtained from patient or his or her legally designated representative (if locally required). * Angiography suite immediately available. * Endovascular treatment team immediately available (Neurologist, Neurointerventionalist, Anesthesiologist, Nursing, Technicians as per local standard practice) Exclusion Criteria: Clinical exclusion criteria: * Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0 * Known baseline platelet count \< 30.000/μL * Baseline blood glucose of \< 50mg/dL (\< 2.78mmol/l) * For patients receiving thrombolysis: severe, sustained hypertension (SBP \> 185 mm Hg or DBP \> 110 mm Hg). Note: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA/ASA guidelines recommended medication (including IV antihypertensive drips), the patient can be enrolled. * Patients from a transfer center (Primary Stroke Center) with a CT/MR that is not required to be redone in the Comprehensive Stroke Center as per discretion of the physician or per local standards (e.g. CT/MR less than 90 minutes old). * Patients in coma (NIHSS item of consciousness \>1) defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation). * Patients with extreme vomiting * Patients that are extremely agitated * Seizures at stroke onset which would preclude obtaining a baseline NIHSS * Serious, advanced, or terminal illness with anticipated life expectancy of less than one year. * Patients acquired stroke while in-hospital * History of life-threatening allergy (more than rash) to contrast medium * Cerebral vasculitis * Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.) * Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas). * Patients with unstable clinical status who require emergent life support care * Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. * Subject participates in a potentially confounding drug or device trial during the course of the study. * Woman of childbearing potential who is known to be pregnant on admission. * Subject meets an exclusion criteria according to national law (e.g. age, pregnant woman, breast feeding woman) * Subject is Philips employee or their family members residing with this Philips employee.

Contact & Investigator

Central Contact

Gerrits

✉ carin.gerrits@philips.com

📞 +31 6 55 48 29 31

Principal Investigator

Raul G Nogueira

PRINCIPAL INVESTIGATOR

UPMC Stroke Institute, Pittsburgh

Frequently Asked Questions

Who can join the NCT04701684 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04701684 currently recruiting?

Yes, NCT04701684 is actively recruiting participants. Contact the research team at carin.gerrits@philips.com for enrollment information.

Where is the NCT04701684 trial being conducted?

This trial is being conducted at Jacksonville, United States, Atlanta, United States, The Bronx, United States, José Hernández, Argentina and 11 additional locations.

Who is sponsoring the NCT04701684 clinical trial?

NCT04701684 is sponsored by Philips Clinical & Medical Affairs Global. The principal investigator is Raul G Nogueira at UPMC Stroke Institute, Pittsburgh. The trial plans to enroll 594 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology